MBX Biosciences Inc’s filing revealed that its Director Heron Patrick J acquired Company’s shares for reported $12.0 million on Sep 26 ’25. In the deal valued at $18.00 per share,666,666 shares were bought. As a result of this transaction, Heron Patrick J now holds 5,219,440 shares worth roughly $84.87 million.
Then, Pescovitz Ora H. bought 7,693 shares, generating $45,312 in total proceeds. Upon buying the shares at $5.89, the Director now owns 24,329 shares.
Before that, GORDON CARL L bought 143,170 shares. MBX Biosciences Inc shares valued at $1,551,963 were divested by the Director at a price of $10.84 per share. As a result of the transaction, GORDON CARL L now holds 3,255,000 shares, worth roughly $52.93 million.
A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in early August with a ‘”an Outperform”‘ rating. Oppenheimer began covering MBX with “an Outperform” recommendation on July 16, 2025. Citizens JMP started covering the stock on April 10, 2025. It rated MBX as “a Mkt outperform”.
Price Performance Review of MBX
On Monday, MBX Biosciences Inc [NASDAQ:MBX] saw its stock fall -2.58% to $16.26. Over the last five days, the stock has lost -9.36%. MBX Biosciences Inc shares have fallen nearly -30.98% since the year began. Nevertheless, the stocks have fallen -11.77% over the past one year. While a 52-week high of $27.50 was reached on 09/22/25, a 52-week low of $4.81 was recorded on 04/07/25.
Levels Of Support And Resistance For MBX Stock
The 24-hour chart illustrates a support level at 15.87, which if violated will result in even more drops to 15.49. On the upside, there is a resistance level at 16.77. A further resistance level may holdings at 17.29.
How much short interest is there in MBX Biosciences Inc?
A steep rise in short interest was recorded in MBX Biosciences Inc stocks on 2025-09-15, growing by 0.16 million shares to a total of 4.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 4.07 million shares. There was a rise of 3.81%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
